Oppenheimer & Co. Inc. purchased a new position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 6,497 shares of the company’s stock, valued at approximately $711,000. Oppenheimer & Co. Inc. owned 0.07% of VanEck Pharmaceutical ETF as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also modified their holdings of the stock. NTV Asset Management LLC purchased a new position in VanEck Pharmaceutical ETF during the third quarter worth approximately $661,000. Axxcess Wealth Management LLC increased its position in shares of VanEck Pharmaceutical ETF by 2.0% in the third quarter. Axxcess Wealth Management LLC now owns 9,741 shares of the company’s stock valued at $1,066,000 after buying an additional 188 shares in the last quarter. Strategy Asset Managers LLC purchased a new stake in shares of VanEck Pharmaceutical ETF in the third quarter valued at approximately $266,000. Avior Wealth Management LLC acquired a new position in shares of VanEck Pharmaceutical ETF during the 3rd quarter worth approximately $1,685,000. Finally, Rye Brook Capital LLC raised its stake in shares of VanEck Pharmaceutical ETF by 4.3% during the 3rd quarter. Rye Brook Capital LLC now owns 70,255 shares of the company’s stock worth $7,691,000 after buying an additional 2,925 shares during the period.
VanEck Pharmaceutical ETF Stock Performance
VanEck Pharmaceutical ETF stock opened at $122.11 on Thursday. The stock has a market capitalization of $1.12 billion, a P/E ratio of 20.21 and a beta of 0.45. The company’s fifty day moving average price is $112.77 and its 200 day moving average price is $108.17. VanEck Pharmaceutical ETF has a 1 year low of $92.60 and a 1 year high of $122.13.
VanEck Pharmaceutical ETF Cuts Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, October 6th. Stockholders of record on Thursday, October 1st were given a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 1.2%. This is a negative change from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248. The ex-dividend date was Thursday, October 1st.
VanEck Pharmaceutical ETF Company Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Stories
- Five stocks we like better than VanEck Pharmaceutical ETF
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
